Hepatocellular Carcinoma
Advertisement
Rising HCC mortality rates in the US highlight stark disparities across age, sex, race, and liver disease etiologies.
Kaplan-Meier curves showed that patients with high TBS had significantly decreased OS and increased recurrence rates.
A recent analysis reviewed patient-level data to identify the relationship between pathological response and relapse.
Dr. Richard Finn provides an overview of the key studies in liver cancer from ESMO 2024.
A study compared the outcomes of patients with HCC who underwent upfront surgical resection versus neoadjuvant immunotherapy.
Dr. Amit Mahipal discusses a recent study on atezolizumab plus bevacizumab as a first-line treatment for HCC.
Dr. Dan Kaufman discusses recent research on TGF-β and how it is linked to the development of HCC.
While immunotherapy paired with VEGF inhibitors are considered first-line options, they only provide modest efficacy.
Dr. Luo describes the performance of the two-fusion gene + α-fetal protein logistic regression model.
Dr. Luo explains the potential benefits of machine learning for patients with hepatocellular carcinoma.
While TACE is a common treatment for HCC, the procedure alone is associated with unsatisfactory survival benefits.
Dr. Luo and colleagues identified a need for increased screening measures for patients with HCC.
[68Ga]Ga-RYZ-GPC3 shows high specificity in detecting hepatocellular carcinoma, outperforming conventional imaging.
Researchers conducted a comprehensive analysis to determine the association between HCC disease stage and prognosis.
A review analyzed 30 meta-analyses to determine the association between pretreatment NLR and immunotherapy outcomes.
Atezolizumab/bevacizumab and lenvatinib have both shown efficacy as first-line treatments for hepatocellular carcinoma.
The latest guideline update includes recommendations for first-, second-, and third-line therapy options.
Ablative therapy is an important treatment option for achieving a cancer-free state as HCC rates continue to rise.
Researchers found that patients with diabetes and higher alpha-fetoprotein had decreased OS rates.
In patients with HCC, a high CD8 and low TIM3 expression is linked to better OS than PD-1/PD-L1.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.